The current COVID-19 pandemic has raised a major challenge to healthcare systems. Deployment of telehealth solutions can help maintaining continuity of care while limiting pts' and healthcare workers’ exposure with the virus. In this context, Gustave Roussy Cancer Institute has implemented a pts reported outcome platform (CAPRI-COVID) to improve monitoring and effective management of COVID-19 positive pts with cancer.
CAPRI-COVID consists in a mobile application (CAPRI App) and a telephone platform with a dedicated call number, the entire procedure being managed by four NNs. After an initial assessment by the NNs, remote monitoring of 6 COVID-related symptoms were collected daily, either by the patient via the CAPRI App or by NNs during a phone call. In case of worsening or emerging symptoms, an automated alert was sent to the platform; NN assessed the clinical condition and could ask for a medical advice if necessary. The monitoring period was 14 days (with at least 2 days with complete regression of symptoms). Each intervention performed by NNs was tracked on the platform, as well as pts-reported data. This analysis presents the data collected via the platform from March 23 to May 4 2020.
Overall, 116 COVID-positive pts have completed the monitoring period (median age: 58.5 years, 21-90; 56.9% female). 54.3% were monitored after hospitalization for COVID-19, 37.1% after RT-PCR screening (symptomatic pts) and 8.6% for systematic screening prior to surgery. There were no deaths or admissions to intensive care unit. 7.8% of pts were hospitalized (excluding scheduled hospitalization). NNs conducted an average of 9.9 calls per patient. Of 53 events requiring a medical opinion, 50.9% resulted in a visit to the emergency room. 41.4% of pts downloaded the CAPRI App, and completed the tracking data on average 1.1 times per day.
CAPRI-COVID enabled to keep the majority of pts at home, and helped to ensure secure pts’ pathways during this epidemic. NNs play an essential role in addition with the use of CAPRI App which helped limiting phone calls and focusing on the management of complex pts. Ongoing analyses are exploring actions of NNs and pts’ experience.
Gustave Roussy.
Has not received any funding.
O. Mir: Honoraria (self), Travel/Accommodation/Expenses: Amgen; Honoraria (self), Honoraria (institution): AstraZeneca ; Honoraria (self), Research grant/Funding (institution): Bayer; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Blueprint Medicines ; Honoraria (self): Bristol-Myers Squibb ; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Eli Lilly ; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Shareholder/Stockholder/Stock options: Ipsen; Honoraria (self): Lundbeck ; Honoraria (self): MSD; Honoraria (self), Honoraria (institution): Novartis; Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer ; Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Honoraria (self), Speaker Bureau/Expert testimony: Servier; Honoraria (self): Vifor Pharma ; Shareholder/Stockholder/Stock options: Amplitude Surgical ; Honoraria (self), Shareholder/Stockholder/Stock options: Transgene ; Honoraria (institution): PharmaMar. F. Scotté: Honoraria (self): CIO Roche; Honoraria (self): MSD; Honoraria (self): Pierre fabre Oncology; Honoraria (self): Leo Pharma; Honoraria (self): BMS; Honoraria (self): Pfizer; Honoraria (self): Mundi Pharma; Honoraria (self): Mylan. All other authors have declared no conflicts of interest.